Sai Parenterals files DRHP with SEBI to raise ₹285 crore via IPO
Sai Parenterals filed DRHP for a ₹285 crore IPO, with proceeds to fund expansion, debt reduction, and overseas acquisition.
Live Market Updates
Latest Financial News
Stay ahead with real-time financial news, market insights, and expert analysis from trusted sources worldwide
News Feed
1 articles
Live Market Updates
Latest Financial News
Stay ahead with real-time financial news, market insights, and expert analysis from trusted sources worldwide
positive
5h agoSai Parenterals files DRHP with SEBI to raise ₹285 crore via IPO
Sai Parenterals Limited, a Hyderabad-based pharmaceutical manufacturer, has filed its Draft Red Herring Prospectus (DRHP) with SEBI to raise ₹285 crore through a public issue. The offer includes a fresh issue of ₹285 crore and an offer-for-sale (OFS) of up to 35 lakh shares. The proceeds will be used for R&D expansion, working capital, debt repayment, and the acquisition of Noumed Pharmaceuticals in Australia. Arihant Capital is acting as the book-running lead manager for the issue.
positive
5h agoSai Parenterals files DRHP with SEBI to raise ₹285 crore via IPO
Sai Parenterals Limited, a Hyderabad-based pharmaceutical manufacturer, has filed its Draft Red Herring Prospectus (DRHP) with SEBI to raise ₹285 crore through a public issue. The offer includes a fresh issue of ₹285 crore and an offer-for-sale (OFS) of up to 35 lakh shares. The proceeds will be used for R&D expansion, working capital, debt repayment, and the acquisition of Noumed Pharmaceuticals in Australia. Arihant Capital is acting as the book-running lead manager for the issue.
Breaking
positive
Sai Parenterals files DRHP with SEBI to raise ₹285 crore via IPO
about 6 hours ago
1 min read
76 words
Sai Parenterals filed DRHP for a ₹285 crore IPO, with proceeds to fund expansion, debt reduction, and overseas acquisition.
Sai Parenterals Limited, a Hyderabad-based pharmaceutical manufacturer, has filed its Draft Red Herring Prospectus (DRHP) with SEBI to raise ₹285 crore through a public issue. The offer includes a fresh issue of ₹285 crore and an offer-for-sale (OFS) of up to 35 lakh shares. The proceeds will be used for R&D expansion, working capital, debt repayment, and the acquisition of Noumed Pharmaceuticals in Australia. Arihant Capital is acting as the book-running lead manager for the issue.
Sai Parenterals Limited, a Hyderabad-based pharmaceutical manufacturer, has filed its Draft Red Herring Prospectus (DRHP) with SEBI to raise ₹285 crore through a public issue. The offer includes a fresh issue of ₹285 crore and an offer-for-sale (OFS) of up to 35 lakh shares. The proceeds will be used for R&D expansion, working capital, debt repayment, and the acquisition of Noumed Pharmaceuticals in Australia. Arihant Capital is acting as the book-running lead manager for the issue.
Companies:
Sai Parenterals Limited
Noumed Pharmaceuticals
Tags:
Sai Parenterals
pharma IPO
Sai Parenterals
pharma IPO
DRHP
SEBI
Arihant Capital
Source: